Zosano Pharma Corp represents a commitment to providing innovative therapies in the pharmaceutical industry. With a focus on developing effective treatments, Zosano Pharma Corp values scientific research, collaboration, and patient well-being. Their corporate philosophy revolves around improving patient outcomes and enhancing the quality of life. The company prioritizes integrity, transparency, and accountability in all aspects of their operations. Zosano Pharma Corp consistently strives to utilize cutting-edge technologies and scientific advancements to address unmet medical needs. Through their dedication to excellence, Zosano Pharma Corp aims to make a positive impact on healthcare and bring transformative solutions to patients worldwide.

Zosano Pharma Corp mainly operates in the United States.

Zosano Pharma Corp has achieved several significant milestones. The company successfully completed a Phase 3 clinical trial for its lead drug candidate, Qtrypta, which is a novel transdermal microneedle patch for the acute treatment of migraines. Additionally, Zosano Pharma Corp obtained approval from the U.S. Food and Drug Administration (FDA) to proceed with the New Drug Application (NDA) for Qtrypta. Furthermore, the company has established collaborations with pharmaceutical giants, such as Beijing Fangpusun Life Science Technology Co., Ltd, for the commercialization of Qtrypta in China. With these achievements, Zosano Pharma Corp has demonstrated its commitment to developing innovative solutions for the treatment of various medical conditions.

Zosano Pharma Corp is a pharmaceutical company with a notable history and background. Established in 2006, Zosano focuses on developing innovative therapies for various medical conditions. The company is dedicated to improving patient outcomes through its unique drug delivery system, known as the Zosano Delivery Platform. This platform offers convenient and efficient administration of therapeutics through microneedle patch technology. Zosano Pharma Corp has a diverse pipeline of potential treatments that target therapeutic areas like migraine, epilepsy, and osteoporosis. With a commitment to advancing drug delivery methods, Zosano Pharma Corp aims to revolutionize the pharmaceutical industry and improve the lives of patients worldwide.

The main competitors of Zosano Pharma Corp in the market include pharmaceutical companies such as Pfizer, Novartis, Johnson & Johnson, and GlaxoSmithKline. These companies are prominent players in the pharmaceutical industry, known for their extensive product portfolios and strong market presence. Zosano Pharma Corp faces competition from these established players in areas such as research and development, product innovation, and market share. It is important for Zosano Pharma Corp to differentiate itself through unique offerings and strategic partnerships in order to maintain a competitive edge in the industry.

Zosano Pharma Corp is primarily active in the pharmaceutical industry.

The business model of Zosano Pharma Corp is centered around the development and commercialization of innovative therapeutic products in the healthcare industry. As a biopharmaceutical company, Zosano focuses on using its proprietary drug delivery technologies to improve patient outcomes and enhance the delivery of drugs. With a strong emphasis on developing novel therapies, Zosano Pharma Corp aims to address unmet medical needs and provide effective treatment options for various medical conditions. By leveraging its expertise and research capabilities, Zosano Pharma Corp strives to create value for patients, healthcare providers, and investors.

Zosano Pharma P/E suhe on −0,97.

Zosano Pharma KUV on 0.

AlleAktien kvaliteediskoor ettevõttele Zosano Pharma on 1/10.

Praegu ei saa Zosano Pharma käivet arvutada.

oodatud Zosano Pharma kasum on −659 276,50 USD.

Zosano Pharma Corp is a biopharmaceutical company specializing in the research and development of new therapies for various diseases. The company's business model is based on the development and commercialization of innovative therapy options based on technologies such as microneedles and special formulations. The company has several focuses, including the treatment of migraine, osteoporosis, and diabetes. For each of these diseases, Zosano Pharma has developed a specialized product portfolio based on the unique needs of patients. The company's key product is the Qtrypta Nasal Spray, used for the treatment of migraine. Qtrypta is based on microneedle technology and allows for rapid absorption of the active ingredient through the nasal mucosa. This leads to rapid pain relief in migraine patients. The company has already achieved positive clinical results for Qtrypta, and it is expected to be approved by the US Food and Drug Administration (FDA) in the near future. Zosano Pharma has also been working on osteoporosis treatments and has developed the product M207. M207 is a patch applied to the skin and contains an active ingredient that improves bone metabolism and reduces the risk of fractures in osteoporosis patients. The company has also achieved positive clinical results for M207 and hopes for its approval soon. In addition to developing therapy options, Zosano Pharma has entered into partnerships with other companies and institutions to enhance its research and development activities and maximize the potential of its innovations. The company also aims to expand into international markets and seeks approval for its products in Europe and other regions of the world. Overall, Zosano Pharma has a business model based on the research of new therapies and innovations. The company relies on technologies such as microneedles and special formulations to achieve faster and more effective results for patients. Through partnerships and strategic initiatives, the company aims for a global presence and growth to unlock the full potential of its research and development.

Zosano Pharma maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Zosano Pharma jaoks arvutada või ettevõte ei maksa dividende välja.

Zosano Pharma ISIN on US98979H2022.

Zosano Pharma WKN on A2JSFT.

Zosano Pharma tähis on ZSAN.

Viimase 12 kuu jooksul maksis Zosano Pharma dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Zosano Pharma tõenäoliselt dividendi summas 0 USD.

Zosano Pharma praegune dividenditootlus on .

Zosano Pharma maksab kvartaalset dividendi. See makstakse välja kuudel .

Zosano Pharma maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Zosano Pharma on liigitatud sektorisse 'Tervis'.

Viimase Zosano Pharma dividendide saamiseks 1.11.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 1.11.2024.

Viimane dividendimakse toimus 1.11.2024.

Aastal 2023 maksis Zosano Pharma 0 USD dividende.

Zosano Pharma dividendid makstakse välja USD.